查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606281

支氣管擴張藥物市場：按藥物類別、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Bronchiectasis Drugs Market by Drug Class (Anti-inflammatory Agents, Antibiotics, Bronchodilators), Route of Administration (Inhalation, Intravenous, Oral), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年支氣管擴張藥物市值為13.9億美元，預計2024年將達15億美元，複合年成長率為9.86%，預計到2030年將達27億美元。

支氣管擴張藥物市場涵蓋了旨在治療支氣管擴張的特定藥物領域，支氣管擴張是一種以肺部部分氣道永久性擴大為特徵的疾病。這個市場包括抗生素、祛痰劑、皮質類固醇和支氣管擴張劑，這些對於治療慢性病和預防疾病進展至關重要。呼吸系統疾病盛行率的上升、人口老化以及對支氣管擴張的認知和診斷的提高推動了對這些藥物的需求。其主要用途是在臨床治療中改善肺功能、減少病情惡化、控制與支氣管擴張相關的細菌感染。主要終端使用者為醫院、居家醫療、專科診所和研究機構，消費族群多元化。成長要素包括藥物開發的進步、醫療成本的上升以及對個人化醫療的重視。新的商機在於生物製藥和基因療法等新治療方法的開發。公司可以透過投資研發以及與研究機構建立策略聯盟來利用這些優勢。然而，市場成長受到治療成本高、新興市場認知度低以及監管核准複雜等因素的阻礙。與學名藥的競爭也是一個限制因素。創新潛力存在於開發具有更好遞送機制的藥物（例如吸入製劑）以及進一步研究和開發用於早期疾病檢測的生物標記。市場是動態的，其特點是不斷的產品創新和監管變化，要求企業保持敏捷和主動。尋求發展的公司必須跟上技術進步和新的處理技術，才能有效地利用新的市場機會。強大的供應鏈管理、先進的合作夥伴關係以及產品組合多元化（包括滿足不同患者需求的產品）對於獲得競爭優勢至關重要。

主要市場統計
基準年[2023] 13.9億美元
預計年份 [2024] 15億美元
預測年份 [2030] 27億美元
複合年成長率（%） 9.86%

市場動態：揭示快速發展的支氣管擴張藥物市場的關鍵市場洞察

支氣管擴張藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 呼吸道感染疾病和疾病增加
    • 政府提高呼吸系統健康意識的舉措
    • 短效和長效支氣管擴張藥物的進入
  • 市場限制因素
    • 病原體對常見支氣管擴張藥物的抗藥性
  • 市場機會
    • 導致吸入抗生素和先進支氣管擴張劑開發的創新
    • 支氣管擴張治療藥物的研發活動和臨床試驗
  • 市場挑戰
    • 關於支氣管擴張藥物的安全性和有效性的監管問題

波特的五力策略工具駕馭支氣管擴張藥物市場

波特的五力架構是了解支氣管擴張藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解支氣管擴張藥物市場的外部影響

外部宏觀環境因素在塑造支氣管擴張藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解支氣管擴張治療藥物市場的競爭狀況

支氣管擴張治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣支氣管擴張藥物市場供應商的績效評估

FPNV 定位矩陣是評估支氣管擴張藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，繪製支氣管擴張藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對支氣管擴張藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 呼吸道感染疾病和疾病增加
      • 政府採取措施提高人們對呼吸系統健康的認知
      • 短效和長效支氣管擴張藥物的進入
    • 抑制因素
      • 對常見病原體抗藥性的支氣管擴張藥物
    • 機會
      • 導致吸入抗生素和先進支氣管擴張劑開發的創新
      • 支氣管擴張治療藥物的研發活動和臨床試驗
    • 任務
      • 關於支氣管擴張藥物的安全性和有效性的監管問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的支氣管擴張藥物市場

  • 發炎劑
  • 抗生素
  • 支氣管擴張劑
  • 黏液溶解藥物

第7章支氣管擴張藥物市場：依給藥途徑

  • 吸入
  • 靜脈
  • 口服

第8章支氣管擴張藥物市場：依最終用戶分類

  • 診所
  • 醫院
  • 調查機構

第9章北美和南美支氣管擴張藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區支氣管擴張藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲支氣管擴張藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AdvaCare Pharma
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market was valued at USD 1.39 billion in 2023, expected to reach USD 1.50 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.70 billion by 2030.

The bronchiectasis drugs market encompasses a specific sector of pharmaceuticals aimed at treating bronchiectasis, a condition characterized by permanent enlargement of parts of the airways in the lungs. This market's scope includes antibiotics, expectorants, corticosteroids, and bronchodilators, essential in managing chronic symptoms and preventing disease progression. The necessity for these drugs is driven by the rising prevalence of respiratory diseases, aging populations, and increasing awareness and diagnosis of bronchiectasis. Applications primarily revolve around clinical therapies to improve lung function, reduce exacerbations, and manage bacterial infections associated with the condition. Key end-users are hospitals, homecare, specialty clinics, and research institutions, highlighting a diverse consumer base. Influencing growth factors include advancements in drug development, increasing healthcare expenditure, and a stronger emphasis on personalized medicine. Emerging opportunities lie in the development of novel therapies, such as biologics and gene therapy, which promise targeted treatments with improved efficacy. Companies can capitalize on these by investing in R&D and forming strategic alliances with research institutes. However, market growth is challenged by factors such as high treatment costs, limited awareness in developing regions, and complex regulatory approvals. Competition from generic drugs also presents a limitation. Innovation potential exists in developing drugs with better delivery mechanisms, such as inhalable formulations, and conducting further research into biomarkers for early disease detection. The market is dynamic, characterized by constant product innovation and regulatory changes, requiring businesses to maintain agility and foresight. Companies seeking growth should stay abreast of technological advancements and emerging therapeutic techniques to harness new market opportunities effectively. Robust supply chain management, advanced collaborations, and diversification of portfolios to include products addressing varied patient needs will be crucial in gaining a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 1.39 billion
Estimated Year [2024] USD 1.50 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 9.86%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of respiratory tract infections and diseases
    • Government initiatives to raise awareness about respiratory health
    • Entry of short-acting and long-acting bronchiectasis drugs
  • Market Restraints
    • Resistance of pathogenic species to common bronchiectasis drugs
  • Market Opportunities
    • Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
    • R&D activities and clinical trials to develop bronchiectasis drugs
  • Market Challenges
    • Regulatory concerns about the safety and efficacy of bronchiectasis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Bronchiectasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchiectasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchiectasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchiectasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchiectasis Drugs Market

A detailed market share analysis in the Bronchiectasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchiectasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchiectasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchiectasis Drugs Market

A strategic analysis of the Bronchiectasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiectasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchiectasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-inflammatory Agents, Antibiotics, Bronchodilators, and Mucolytics.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, and Oral.
  • Based on End-Users, market is studied across Clinic, Hospital, and Research Institute.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of respiratory tract infections and diseases
      • 5.1.1.2. Government initiatives to raise awareness about respiratory health
      • 5.1.1.3. Entry of short-acting and long-acting bronchiectasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Resistance of pathogenic species to common bronchiectasis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
      • 5.1.3.2. R&D activities and clinical trials to develop bronchiectasis drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns about the safety and efficacy of bronchiectasis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchiectasis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Agents
  • 6.3. Antibiotics
  • 6.4. Bronchodilators
  • 6.5. Mucolytics

7. Bronchiectasis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Bronchiectasis Drugs Market, by End-Users

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Hospital
  • 8.4. Research Institute

9. Americas Bronchiectasis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bronchiectasis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bronchiectasis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim International GmbH
  • 4. Cipla Limited
  • 5. GlaxoSmithKline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Lupin Limited
  • 8. Mylan Inc. by Viatris Inc.
  • 9. Nephron Pharmaceuticals Corporation
  • 10. Novartis AG
  • 11. Perrigo Company PLC
  • 12. Pfizer Inc.
  • 13. Prasco Laboratories
  • 14. Ralington Pharma LLP
  • 15. Steris Healthcare Pvt. Ltd.
  • 16. Sun Pharmaceutical Industries Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. Zydus Group

LIST OF FIGURES

  • FIGURE 1. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIECTASIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIECTASIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023